Is a complete KYTX research report available?

No complete published report is available for Kyverna Therapeutics, Inc. (KYTX) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Kyverna Therapeutics, Inc. (KYTX)

NASDAQ: KYTX · USD

$7.49

+0.42 (+5.9%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first KYTX analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	455.4M
Net income (ttm)	-156.4M
EPS (ttm)	-$3.22
Shares out	60.8M
Volume	642,415
Beta	1.88
Price target	$30.4	+305.9%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -156.4M
EPS (ttm): -$3.22
Market cap: 455.4M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All KYTX indicators

Market & fundamental data

Available fields

185

Groups with data

Currency

USD

Showing 185 of 185 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001994702
Company name	Kyverna Therapeutics, Inc.
Country	United States
Country code	US
Cusip	501976104
Employees	129
Employees Change	10%
Employees Change Percent	8.4
Enterprise value	$252.7M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2024-02-08
Isin	US5019761049
Last refreshed	2026-07-31
Market cap	$455.4M
Market cap category	Small-Cap
Price	$7.49
Price currency	USD
Sector	Healthcare
Sector PE	45.21
Sector PE Fwd	23.64
Sic	2836
Symbol	KYTX
Website	https://kyvernatx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-34.35%
EV Sales Forward	505.33x
FCF yield	-33.03%
P/B ratio	2.32x
PS Forward	910.71x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-126.4M
Net Income	$-156.4M
Net Income Growth Quarters	1%
Net Income Growth Years	0%
Profit Per Employee	$-1.2M
ROA	-39.55
ROCE	-72.04
ROE	-74.55
ROIC	-44.48

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	94.63%
EPS Growth Quarters	2
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$257M
Cash	$236.4M
Current Assets	$241.7M
Current Liabilities	$29.7M
Debt	$33.8M
Debt Equity	$0.17
Equity	$195.6M
Interest Coverage	-144.8
Liabilities	$61.4M
Long Term Assets	$15.3M
Long Term Liabilities	$31.8M
Net Cash	$202.7M
Net Cash By Market Cap	$44.51
Net Cash Growth	-14.01%
Net Debt Equity	$-1.04
Tangible Book Value	$195.6M
Tangible Book Value Per Share	$3.23
WACC	13.75

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	8.15
Net Working Capital	$-22.4M
Quick ratio	7.97
Working Capital	$212.1M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-12.42%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	94.55%
200-day SMA	8.27
50-day SMA	8.18
50-day SMA vs 200-day SMA	50under200
All Time High	35.06
All Time High Change	-78.64%
All Time High Date	2024-02-08
All Time Low	1.78
All Time Low Change	320.79%
All Time Low Date	2025-04-17
ATR	0.56
Beta	1.88
Beta1y	1.84
Beta2y	1.86
Ch YTD	-20.32
High	7.58
High52	13.67
High52 Date	2025-12-15
High52ch	-45.21%
Low	7.21
Low52	2.8
Low52 Date	2025-08-12
Low52ch	167.5%
Ma50ch	-8.46%
Premarket Change Percent	1.84
Premarket Price	$7.2
Premarket Volume	3,983
Price vs 200-day SMA	-9.41%
RSI	44.55
RSI Monthly	33.1
RSI Weekly	46.19
Sharpe ratio	1.12x
Sortino ratio	1.83
Total Return	-12.42%
Tr YTD	-20.32
Tr1m	-14.69%
Tr1w	2.74%
Tr3m	-10.83%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	6
Analyst Count Top	4
Analyst Price Target Top	$29
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.68
Operating Income	$-163.8M
Price target	$30.4
Price Target Change	$306
Price Target Change Top	$287

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	35,545,730%
Float Percent	58.47%
Net Borrowing	24,147,000
Shares Insiders	1.84%
Shares Institutions	40.26%
Shares Out	60,795,212
Shares Qo Q	28.16%
Shares Yo Y	12.42%
Short Float	22.07%
Short Ratio	5.51
Short Shares	12.91

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-161.5M
Adjusted OCF	-161,484,000
Average Volume	1,163,528.55x
Bv Per Share	3.23
CAPEX	$-5,000
Ch1m	-14.69
Ch1w	2.74
Ch1y	94.55
Ch3m	-10.83
Ch6m	-8.77
Change	5.94%
Change From Open	3.45
Close	7.07
Days Gap	2.4
Depreciation Amortization	1,649,000
Dollar Volume	4,811,688.4
Earnings Date	2026-08-12
Earnings Time	amc
EBIT	$-163.8M
EBITDA	$-162.1M
EPS	$-3.22
F Score	2
FCF	$-150.4M
FCF EV Yield	-59.53x
FCF Per Share	$-2.47
Financing CF	141,481,000
Fiscal Year End	December
Founded	2,018
Investing CF	-15,764,000
Ipr	-65.95
Iprfo	-78.13
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-12
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-26
Ma150	8.56
Ma150ch	-12.48%
Ma20	8.06
Ma20ch	-7.01%
Net CF	-24,677,000
Next Earnings Date	2026-08-11
Open	7.24
Optionable	Yes
Position In Range	75.68
Post Close	7.49
Postmarket Change Percent	0.27
Postmarket Price	$7.51
Ppne	9,733,000
Pre Close	7.07
Price Date	2026-07-30
Ptbv Ratio	2.33
Relative Volume	0.55x
Share Based Comp	11,090,000
Tr6m	-8.77%
Us State	California
Volume	642,415

Kyverna Therapeutics, Inc. (KYTX)

Coverage state: Market snapshot only — no published research

Generate the first KYTX analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · KYTX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All KYTX indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on KYTX

Frequently asked questions